Table 1.
Clinicopathological characteristics of the training and validation cohorts
| Variables | Entire cohort | Training cohort | Validation cohort |
|---|---|---|---|
| [n (%)] | [n (%)] | [n (%)] | |
| No. of patients | 165 | 110 | 55 |
| Age, years | |||
| ≤ 45 | 63 (38.18) | 41 (37.27) | 22 (40.00) |
| > 45 | 102 (61.82) | 69 (62.73) | 33 (60.00) |
| BMI, kg/m2 | |||
| < 25 | 121 (73.33) | 82 (74.55) | 39 (70.91) |
| ≥ 25 | 44 (26.67) | 28 (25.45) | 16 (29.09) |
| Menopausal status | |||
| Postmenopausal | 77 (46.67) | 51 (46.36) | 26 (47.27) |
| Premenopausal | 88 (53.33) | 59 (53.64) | 29 (52.73) |
| Multifocality | |||
| Multifocal | 37 (22.42) | 24 (21.82) | 13 (23.64) |
| Unifocal | 128 (77.58) | 86 (78.18) | 42 (76.36) |
| Local invasion | |||
| Yes | 7 (4.24) | 6 (5.45) | 1 (1.82) |
| No | 158 (95.76) | 104 (94.55) | 54 (98.18) |
| LVI | |||
| Absent | 124 (75.15) | 83 (75.45) | 41 (74.55) |
| Present | 41 (24.85) | 27 (24.55) | 14 (25.45) |
| Clinical tumor size | |||
| T1 | 19 (11.52) | 13 (11.82) | 6 (10.91) |
| T2 | 123 (74.55) | 82 (74.55) | 41 (74.55) |
| T3 | 23 (13.94) | 15 (13.64) | 8 (14.55) |
| Lymph node status | |||
| N0 | 52 (31.52) | 37 (33.64) | 15 (27.27) |
| N1-2 | 113 (68.48) | 73 (66.36) | 40 (72.73) |
| Histological grade | |||
| I–II | 53 (32.12) | 40 (36.36) | 13 (23.64) |
| III | 112 (67.88) | 70 (63.64) | 42 (76.36) |
| Histological type | |||
| IDC | 152 (92.12) | 102 (92.73) | 50 (90.91) |
| Others | 13 (7.88) | 8 (7.27) | 5 (9.09) |
| Estrogen receptor | |||
| Negative | 83 (50.30) | 57 (51.82) | 26 (47.27) |
| Positive | 82 (49.70) | 53 (48.18) | 29 (52.73) |
| Progesterone receptor | |||
| Negative | 111 (67.27) | 74 (67.27) | 37 (67.27) |
| Positive | 54 (32.73) | 36 (32.73) | 18 (32.73) |
| Hormone receptor | |||
| Negative | 82 (49.70) | 56 (50.91) | 26 (47.27) |
| Positive | 83 (50.30) | 54 (49.09) | 29 (52.73) |
| HER2 | |||
| Negative | 84 (50.91) | 55 (50.00) | 29 (52.73) |
| Positive | 81 (49.09) | 55 (50.00) | 26 (47.27) |
| Ki67 | |||
| ≤ 30 | 131 (79.39) | 91 (82.73) | 40 (72.73) |
| > 30 | 34 (20.61) | 19 (17.27) | 15 (27.27) |
| Biological subtype | |||
| Luminal B | 45 (27.27) | 29 (26.36) | 16 (29.09) |
| HER2-enriched | 69 (41.82) | 47 (42.73) | 22 (40.00) |
| Triple-negative | 51 (30.91) | 34 (30.91) | 17 (30.91) |
| NCT regimen | |||
| TEC | 86 (52.12) | 57 (51.82) | 29 (52.73) |
| TCbH | 79 (47.88) | 53 (48.18) | 26 (47.27) |
| NCT time | |||
| ≤ 4 | 28 (16.97) | 23 (20.91) | 5 (9.09) |
| > 4 | 137 (83.03) | 87 (79.09) | 50 (90.91) |
| Hemoglobin, g/L | |||
| < 110 | 14 (8.48) | 9 (8.18) | 5 (9.09) |
| ≥ 110 | 151 (91.52) | 101 (91.82) | 50 (90.91) |
| MP stage | |||
| SD/PD | 37 (22.42) | 30 (27.27) | 7 (12.73) |
| PR/CR | 128 (77.58) | 80 (72.73) | 48 (87.27) |
BMI body mass index, HER2 human epidermal growth factor receptor 2, IDC intraductal carcinoma, LVI lymphovascular invasion, NCT neoadjuvant chemotherapy, MP Miller/Payne grading system, SD/PD stable disease/progressive disease, PR/CR partial remission/complete remission, TEC docetaxel + epirubicin + cyclophosphamide, TCbH docetaxel + carboplatin + trastuzumab